162 related articles for article (PubMed ID: 36958430)
21. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
[TBL] [Abstract][Full Text] [Related]
22. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
Lupo KB; Yao X; Borde S; Wang J; Torregrosa-Allen S; Elzey BD; Utturkar S; Lanman NA; McIntosh M; Matosevic S
Nat Commun; 2024 Mar; 15(1):1909. PubMed ID: 38429294
[TBL] [Abstract][Full Text] [Related]
23. Deficits in endogenous adenosine formation by ecto-5'-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis.
Oliveira L; Correia A; Cristina Costa A; Guerra-Gomes S; Ferreirinha F; Magalhães-Cardoso MT; Vilanova M; Correia-de-Sá P
Mediators Inflamm; 2015; 2015():460610. PubMed ID: 25691808
[TBL] [Abstract][Full Text] [Related]
24. Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1.
García-Rocha R; Monroy-García A; Hernández-Montes J; Weiss-Steider B; Gutiérrez-Serrano V; Del Carmen Fuentes-Castañeda M; Ávila-Ibarra LR; Don-López CA; Torres-Pineda DB; de Lourdes Mora-García M
Cytokine; 2019 Jun; 118():71-79. PubMed ID: 30301599
[TBL] [Abstract][Full Text] [Related]
25. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
26. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
27. The roles of CD73 in cancer.
Gao ZW; Dong K; Zhang HZ
Biomed Res Int; 2014; 2014():460654. PubMed ID: 25126561
[TBL] [Abstract][Full Text] [Related]
28. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.
Yegutkin GG; Auvinen K; Rantakari P; Hollmén M; Karikoski M; Grénman R; Elima K; Jalkanen S; Salmi M
Eur J Immunol; 2015 Feb; 45(2):562-73. PubMed ID: 25402681
[TBL] [Abstract][Full Text] [Related]
29. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
Harvey JB; Phan LH; Villarreal OE; Bowser JL
Front Immunol; 2020; 11():508. PubMed ID: 32351498
[TBL] [Abstract][Full Text] [Related]
30. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
[TBL] [Abstract][Full Text] [Related]
31. Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration.
Koszałka P; Gołuńska M; Urban A; Stasiłojć G; Stanisławowski M; Majewski M; Składanowski AC; Bigda J
PLoS One; 2016; 11(3):e0151420. PubMed ID: 26964090
[TBL] [Abstract][Full Text] [Related]
32. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
[TBL] [Abstract][Full Text] [Related]
33. A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway.
Wurm M; Schaaf O; Reutner K; Ganesan R; Mostböck S; Pelster C; Böttcher J; de Andrade Pereira B; Taubert C; Alt I; Serna G; Auguste A; Stadermann KB; Delic D; Han F; Capdevila J; Nuciforo PG; Kroe-Barrett R; Adam PJ; Vogt AB; Hofmann I
Mol Cancer Ther; 2021 Nov; 20(11):2250-2261. PubMed ID: 34482286
[TBL] [Abstract][Full Text] [Related]
34. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion.
Wang M; Jia J; Cui Y; Peng Y; Jiang Y
Cell Death Dis; 2021 Nov; 12(11):1065. PubMed ID: 34753903
[TBL] [Abstract][Full Text] [Related]
35. CD73 on cancer-associated fibroblasts enhanced by the A
Yu M; Guo G; Huang L; Deng L; Chang CS; Achyut BR; Canning M; Xu N; Arbab AS; Bollag RJ; Rodriguez PC; Mellor AL; Shi H; Munn DH; Cui Y
Nat Commun; 2020 Jan; 11(1):515. PubMed ID: 31980601
[TBL] [Abstract][Full Text] [Related]
36. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
[TBL] [Abstract][Full Text] [Related]
37. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
[TBL] [Abstract][Full Text] [Related]
38. Attenuation of Clostridium difficile toxin-induced damage to epithelial barrier by ecto-5'-nucleotidase (CD73) and adenosine receptor signaling.
Schenck LP; Hirota SA; Hirota CL; Boasquevisque P; Tulk SE; Li Y; Wadhwani A; Doktorchik CT; Macnaughton WK; Beck PL; MacDonald JA
Neurogastroenterol Motil; 2013 Jun; 25(6):e441-53. PubMed ID: 23600886
[TBL] [Abstract][Full Text] [Related]
39. Enzyme activity of circulating CD73 in human serum.
Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
[TBL] [Abstract][Full Text] [Related]
40. Adenosine and adenosine receptors in colorectal cancer.
Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
